Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence

NCT01178281 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01178281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01178281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
September 8, 2010
Completion date
May 15, 2018
Enrollment
267 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

mpn-associated myelofibrosis, primary myelofibrosis